
    
      PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are treated with
      intravenous immune globulin or placebo. In the absence of a hypersensitivity reaction to a
      test dose, a total of 11 doses is administered: daily for 5 days, then every 2 weeks for 12
      weeks.

      Patients are followed at 3 months.
    
  